USPTO serial 97446452
LEGEND BIOTECH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 23, 2024
- Examiner
- LORENZO, KATHLEEN H
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with LEGEND BIOTECH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Bridgewater, NJ, US
Nanjing Legend Biotech Co., Ltd.
Nanjing, Jiangsu, CN
Nanjing Legend Biotech Co., Ltd.
Nanjing, Jiangsu, CN
Nanjing Legend Biotech Co., Ltd.
Nanjing, Jiangsu, CN
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Preetha Chakrabarti
Preetha Chakrabarti Crowell & Moring LLP375 Ninth AvenueTwo Manhattan WestNew York, NY 10001Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals and medical preparations for autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical use; biological preparations for medical purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; biological tissue cultures for medical purposes; chemical preparations for medical purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; chemical preparations for pharmaceutical purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; drugs for medical purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; immunostimulants; medicines for human purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; pharmaceutical preparations, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; Pharmaceutical compositions for autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; pharmaceuticals for autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; stem cells for medical purposes; Injectable pharmaceuticals for autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; anti-cancer drugs; Anti-cancer preparations; Compounds for treating cancer; Pharmaceutical preparations and substances for the treatment of cancer; Anti-cancer preparations from hormones and antagonists; Biopharmaceuticals for the treatment of cancer; Biological preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer; Cell growth media for growing cells for medical use; Cells for medical use, Living cells for medical use; vaccine preparation; Medical diagnostic preparations | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research, analysis, and testing in the field of biotechnology and scientific research and design relating thereto; design and development of computer hardware and software; biological research; chemical analysis; chemical research; chemistry services namely research in the field of chemistry; Scientific research in the nature of conducting clinical trials for others; culturing of cells for scientific research purposes, for others; medical research; research and development of new products for others; scientific laboratory services; scientific research; technological research in the field of biotechnology; Cell separation technology research services; Cell separation research services; Cell culture services for scientific and research purposes, for others; Scientific services relating to the isolation and cultivation of human tissues and cells for scientific and research purposes; Scientific research for medical purposes in the area of cancerous diseases; Stem cell research services; Antibody research and development; Pharmaceutical research and development; Medical computer programming | ACTIVE | — |
| 044 | Medical services; alternative medicine services; cultured cell bank services for medical transplantation; health care; health centre services; health counselling; health assessment services; hospital services; medical advice for individuals with disabilities; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical assistance; medical clinic services; medical treatment using cultured cells; preparation of prescriptions by pharmacists; therapy services, namely, immunotherapy, cell therapy, gene therapy, antibody therapy, radiation therapy, or chemotherapy; Medical services relating to the removal, treatment and processing of human cells; Providing cancer screening services; Medical services for the treatment of cancer; Medical analysis services for the diagnosis of cancer; Medical analysis services for cancer diagnosis and prognosis; Medical screening; provision of medical information; stem cell therapy services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LEGEND BIOTECH USA INC.
- Other trademarks owned by Nanjing Legend Biotech Co., Ltd.
- Other trademarks owned by Nanjing Legend Biotech Co., Ltd.
- Other trademarks owned by Nanjing Legend Biotech Co., Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named LEGEND BIOTECH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 6, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 6, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 6, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 6, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 6, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 17, 2024 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 23, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 23, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 7, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 7, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 18, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 5, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 30, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 29, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 29, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 25, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 25, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 25, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 25, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 25, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 20, 2023 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jun 20, 2023 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Mar 29, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 29, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 29, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 17, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jun 16, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 10, 2022 | NWAP | NEW APPLICATION ENTERED | — |